BioTechniques

Are mice reliable models for PD-1 studies?

Mouse PD-1 is significantly weaker than human PD-1, which could have implications for using mice as models in PD-1 studies. Programmed cell death protein 1 (PD-1) has been a key target for cancer ...
FiercePharma

Akeso, Summit's PD-1 bispecific crushes Merck's Keytruda in study, signaling potential new standard in lung cancer

The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. The China-only data are impressive, signaling the PD-1/VEGF bispecific ...
ascopubs.org

Long-Term Follow-Up of Real-World Adjuvant Anti–PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma

NOTE. Extended FU data were received for 490 patients. Eighty-three patients had already died at the time of the 2-year analysis. Nine patients in the PD-1–treated arm and seven patients in the TT arm ...
FiercePharma

ESMO: Akeso, Summit's ivonescimab beats PD-1 in first chemo combo win in 1st-line NSCLC

After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in China, Akeso and Summit Therapeutics’ ivonescimab has shown it can delay ...